ISA Pharmaceuticals obtains broad patent protection in the US for proprietary AMPLIVANT® platform and compounds

ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions

Scientific Review Endorses ISA Pharmaceuticals’ Strategy to Overcome Immune Evasion in Cancer Immunotherapy

ISA Pharmaceuticals Appoints Gerben Moolhuizen as Chief Business Development Officer